New drug cocktail aims to shrink prostate tumors before surgery
NCT ID NCT05873192
First seen Jan 04, 2026 · Last updated Jun 19, 2026 · Updated 32 times
Summary
This phase 2 study is testing whether adding talazoparib to standard hormone therapy and enzalutamide can help men with prostate cancer that has spread to lymph nodes. About 30 participants will take the drug combination before having their prostate removed. The goal is to see if the treatment is safe and effective at controlling the cancer before surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
talazoparib and enzalutamide (drugs)
What this could lead to
If successful, this could lead to a more effective treatment option for men with prostate cancer that has spread to lymph nodes, potentially improving outcomes before surgery.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination may cause side effects like fatigue or blood issues, and it's not yet proven to work better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.